MYC and neoplasm: In agreement with the in vitro results, coadministration of A485 and quizartinib enhanced the inhibition of H3K27Ac, c-Myc and FLT3 signaling, as evidenced by the reduced phosphorylation of STAT5 and ERK in tumor tissues (Fig. 3n; Supplementary Fig. S3f).